A renal cell carcinoma tumorgraft platform to advance precision medicine

Renal cell carcinoma (RCC) encompasses a heterogenous group of tumors, but representative preclinical models are lacking. We previously showed that patient-derived tumorgraft (TG) models recapitulate the biology and treatment responsiveness. Through systematic orthotopic implantation of tumor samples from 926 ethnically diverse individuals into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we generate a resource comprising 172 independently derived, stably engrafted TG lines from 148 individuals. TG lines are characterized histologically and genomically (whole-exome [n = 97] and RNA [n = 102] sequencing). The platform features a variety of histological and oncogenotypes, including TCGA clades further corroborated through orthogonal metabolomic analyses. We illustrate how it enables a deeper understanding of RCC biology; enables the development of tissue-and imaging-based molecular probes; and supports advances in drug development.

Automated summary

By orthotopically implanting tumor samples from ethnically diverse individuals into mice, a resource of 172 independently derived, stably engrafted TG lines has been generated. These lines are characterized histologically and genomically, helping to advance understanding of RCC biology.